SCHEMBL25899172

SCHEMBL25899172

CC(C)(C)c1c[nH]c2[nH]c(N)nc(=O)c12

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.32
PNP P00491 1/20 0.31
CYP3A4 P08684 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25903544 0.81 BACE1 (0.32)
SCHEMBL4722932 0.78 XDH (0.36) PNPCYP3A4BLM
SCHEMBL20202023 0.75 BACE1 (0.36) PNP
SCHEMBL24629142 0.75 TYMS (0.38) PNPCYP3A4BLM
SCHEMBL28919394 0.75 FGFR1 (0.36) PNPCYP3A4BLM
SCHEMBL3793648 0.74 DYRK1A (0.42)
SCHEMBL25899106 0.74 CHEK1 (0.35) PNPCYP3A4BLM
SCHEMBL20206657 0.72 PNP (0.35) PNP
SCHEMBL20202010 0.72 PNP (0.36) PNP
SCHEMBL20792487 0.70 TYMS (0.43) PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, FCGR3B, FCGR2A L3MBTL1 2521/4885PNP 979/4885CYP3A4 4873/4885
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, ASGR1, FCGR3B L3MBTL1 2887/4885PNP 1279/4885CYP3A4 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.